NASDAQ$OCGN
Ocugen Inc · Q4 2019 earnings
Q4 2019 earnings · · Investor relations
Briefing
Reported full year 2019 financial results along with a general business update.
Ocugen reported a net loss of $20.2 million for the year ended December 31, 2019. The company's cash, cash equivalents and restricted cash totaled $7.6 million as of December 31, 2019. Over 95% planned enrollment completed in Phase 3 oGVHD study; topline results anticipated by end of 2020
- Completed over 95% of planned enrollment in Phase 3 trial for OCU300 (oGVHD) with topline results anticipated by the end of the year.
- Nature Gene Therapy published preclinical data related to OCU400, supporting its potential as a broad-spectrum therapy for retinitis pigmentosa.
- Drew down an additional $0.5 million under its loan agreement with EB5 Life Sciences, L.P.
- Cash, cash equivalents and restricted cash totaled $7.6 million as of December 31, 2019, compared to $1.8 million as of December 31, 2018.
Headline financials
Revenue & EPS history
Ocugen · Revenue · Quarterly
$1.53M
Forward guidance
Ocugen is anticipating topline results for OCU300 by the end of the year and continues to advance IND-enabling studies for OCU400 with a Phase 1/2a clinical trial planned for 2021.
Tailwinds
- Completed over 95% of planned enrollment in Phase 3 trial for OCU300 (oGVHD).
- Anticipating topline results for OCU300 by the end of the year.
- Preclinical data for OCU400 published in Nature Gene Therapy.
- Advancing IND-enabling studies for OCU400.
- Phase 1/2a clinical trial planned for OCU400 in 2021.
Headwinds
- Potential impact of ongoing COVID-19 pandemic-related events on programs and plans.
- Net loss of $20.2 million for the year ended December 31, 2019.
- Operating loss of $14.2 million for the year ended December 31, 2019.
- Accumulated deficit of $51,479,824
- Uncertainty regarding future financial performance
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q4 2019
-1.2%
Avg return
Earnings day
-2.7%
Avg return
5 days after
-3.7%
Avg return
30 days after
42%
19 / 45 earnings
Positive
+31.5%
Q1 2016
Best reaction
-27.5%
Q3 2019
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | -1.0% | +1.0% | -12.0% | |
| Q4 2025 | +5.4% | -10.8% | -3.8% | |
| Q3 2025 | -1.4% | -5.6% | -14.7% | |
| Q1 2025 | -2.3% | +0.9% | +53.8% | |
| Q4 2024 | -2.8% | -5.8% | +12.2% | |
| Q3 2024 | -0.9% | -11.3% | -19.4% | |
| Q2 2024 | +5.9% | +11.9% | -3.4% | |
| Q1 2024 | +8.3% | +5.5% | -16.0% | |
| Q4 2023 | -9.4% | -17.0% | +24.5% | |
| Q3 2023 | -6.3% | -2.6% | +1.3% | |
| Q2 2023 | -8.8% | +3.4% | -10.4% | |
| Q1 2023 | +3.3% | +7.3% | -32.1% | |
| Q4 2022 | +2.3% | +6.6% | -15.6% | |
| Q3 2022 | -3.3% | +15.7% | -8.5% | |
| Q2 2022 | +2.9% | +2.2% | -13.4% | |
| Q1 2022 | -12.3% | -19.7% | +0.4% | |
| Q4 2021 | +15.0% | +14.9% | +13.9% | |
| Q3 2021 | -11.4% | -8.4% | -41.3% | |
| Q2 2021 | +8.4% | +5.2% | -0.8% | |
| Q1 2021 | +6.2% | -10.1% | -9.0% | |
| Q4 2020 | -6.6% | -15.4% | -39.5% | |
| Q3 2020 | +1.4% | +3.8% | +8.0% | |
| Q2 2020 | -20.2% | -23.0% | -48.8% | |
| Q1 2020 | +0.0% | -5.2% | -24.2% | |
| Q4 2019 | -15.7% | -19.1% | -11.1% | |
| Q3 2019 | -27.5% | -50.6% | -64.7% | |
| Q2 2019 | +4.3% | -1.1% | +43.9% | |
| Q1 2019 | -4.7% | -8.8% | +54.9% | |
| Q4 2018 | -7.1% | -7.9% | +52.8% | |
| Q3 2018 | -4.7% | -17.8% | -9.3% | |
| Q2 2018 | +6.1% | +17.4% | -68.9% | |
| Q1 2018 | -2.3% | -17.3% | +7.3% | |
| Q4 2017 | -3.3% | -1.3% | -5.3% | |
| Q3 2017 | -5.2% | -9.8% | -9.9% | |
| Q2 2017 | +2.2% | -0.6% | +6.7% | |
| Q1 2017 | -1.2% | -1.2% | +0.0% | |
| Q4 2016 | +1.1% | -9.0% | +0.0% | |
| Q3 2016 | -3.7% | -9.4% | -23.8% | |
| Q2 2016 | +7.1% | +86.4% | +82.8% | |
| Q1 2016 | +31.5% | — | — | |
| Q4 2015 | +8.9% | — | — | |
| Q3 2015 | -16.6% | — | — | |
| Q2 2015 | +3.0% | — | — | |
| Q1 2015 | -2.5% | — | — | |
| Q4 2014 | +4.2% | — | — | |
| Q3 2014 | — | — | — | |
| Q2 2014 | — | — | — | |
| Q1 2014 | — | — | — | |
| Q4 2013 | — | — | — | |
| Q3 2013 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro